Cart
sales@molnova.com
Artemisinic acid
CAS No. 80286-58-4
Artemisinic acid( —— )
Catalog No. M19119 CAS No. 80286-58-4
Artemisinic acid is a major precursor of artemisinin (an antimalaric compound), isolated as the active principles of the medicinal plant Artemisia annua L.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 88 | In Stock |
|
| 25MG | 157 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameArtemisinic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionArtemisinic acid is a major precursor of artemisinin (an antimalaric compound), isolated as the active principles of the medicinal plant Artemisia annua L.
-
DescriptionArtemisinic acid shows antibacterial activity. Artemisinic acid is a major precursor of artemisinin (an antimalaric compound), isolated as the active principles of the medicinal plant Artemisia annua L.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number80286-58-4
-
Formula Weight234.33
-
Molecular FormulaC15H22O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (426.75 mM)
-
SMILESCC1CCC(C2C1CCC(=C2)C)C(=C)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
EIDD-2801
EIDD-2801 is an isopropylester prodrug of the ribonucleoside analog N 4-hydroxycytidine (EIDD-1931) that has shown broad influenza virus and multiple coronaviruses activity.
-
Nigakinone
Nigakinone, isolated from Kumu, is an alkaloid with the pharmacological activity.
-
PAR-4 Agonist Peptid...
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.
